Incidence and outcome of FLT3/ITD mutations in acute myeloid leukemia (AML) grouped according to AML subtype. Incidences are listed as percentages within a given subtype, with the actual patient numbers below in parentheses.
| Study (No. Patients) . | Adult AML . | M3 AML . | Normal/Int Cytogenetics* . | 8:21 or INV16 . | Poor-risk Cytogenetics** AML† . | 20 . | Elderly AML‡ . | Pediatric AML . | Survival . |
|---|---|---|---|---|---|---|---|---|---|
| * Normal and/or intermediate cytogenetics. This included patients with normal cytogenetics (studies 3, 8, 15, 16, and 19) and those lacking 15:17, 8:21, INV16, and poor-risk features. | |||||||||
| ** Poor-risk cytogenetics. This included patients with monosomy 5 or 7, 5q–, 3q–, or complex karyotype. | |||||||||
| † Secondary AML. This was defined as AML arising out of a myelodysplastic syndrome (MDS) and AML with trilineage myelodysplasia. Three of the studies listed (studies 1, 4 and 7) also included treatment-related AML in this group. | |||||||||
| ‡ Elderly AML patients were defined as being > 55 (study 6) or > 60 (study 4) years of age. | |||||||||
| § All 3 patients with high mutant-to-wild-type ratio in this study died. | |||||||||
| 1. Horiike et al (30) | 14.7% (5/34) | ND | |||||||
| 2. Kiyoi et al (74) | 20.3% (15/74) | Decreased | |||||||
| 3. Yamamoto et al (429) | 8.9% (81/429) | 28.0% (23/82) | 11.8% (4/34) | 18.2% (2/11) | Decreased | ||||
| 4. Rombouts et al (75) | 23.7% (14/59) | 24.2% (16/66) | 0.0% (0/6) | 18.2% (2/11) | 22.9% (8/35) | Decreased | |||
| 5. Abu-Duhier et al (106) | 10.0% (1/10) | 22.7% (10/44) | 5.8% (3/52) | Decreased | |||||
| 6. Stirewalt et al (140) | 33.6% (47/140) | No Effect | |||||||
| 7. Kottaridis et al (854) | 26.6% (227/854) | 36.8% (49/133) | 34.2% (96/281) | 8.3% (9/109) | 3.4% (5/147) | 27.4% (17/62) | Decreased | ||
| 8. Whitman et al (82) | 28.0% (23/82) | No Effect | |||||||
| 9. Iwai et al (94) | 5.3% (5/94) | Decreased | |||||||
| 10. Xu et al (87) | 13.8% (12/87) | Decreased | |||||||
| 11. Kondo et al (64) | 10.9% (7/64) | Decreased | |||||||
| 12. Meshinchi et al (91) | 16.5% (15/91) | Decreased | |||||||
| 13. Liang et al (80) | 11.3% (9/80) | No Effect§ | |||||||
| 14. Thiede et al (979) | 22.2% (217/979) | 33.3% (13/39) | 29.7% (134/451) | 4.5% (4/88) | 1.7% (5/298) | 8.8% (3/34) | Decreased | ||
| 15. Schnittger et al (1003) | 23.3.% (234/1003) | 35.8% 24/67) | 39.3% (149/379) | 5.4% (6/11) | 2.7% (3/110) | 15.6% (12/77) | No Effect | ||
| 16. Boissel et al (159) | 25.2% (40/159) | 35.4% (28/79) | 0.0% (0/23) | No Effect | |||||
| 17. Noguera et al (90) | 36.7% (33/90) | No Effect | |||||||
| 18. Frohling et al (523) | 22.8% (119/523) | 39.2% (20/51) | 31.7% (71/224) | 5.7% (4/70) | 2.2% (1/45) | 9.2% (7/76) | Decreased | ||
| 19. Kainz et al (100) | 38.1% (8/21) | 30.2% (16/53) | 7.7% (2/26) | Decreased | |||||
| 20. Moreno et al (208) | 17.3% (36/208) | 0.0% (0.14) | Decreased | ||||||
| 21. Jilani et al (85) | 21.2% (18/85) | Decreased | |||||||
| 22. Arrigoni et al (45) | 22.2% (10/45) | Decreased | |||||||
| 23. Zwaan et al (234) | 11.5% (27/234) | Decreased | |||||||
| TOTAL (4613 adult, 695 pediatric) | 22.9% (986/4299) | 33.6% (163/485) | 32.5% (566/1741) | 6.1% (32/527) | 2.6% (7/617) | 15.6% (46/294) | 31.4% (55/175) | 12.2% (85/695) | |
| Study (No. Patients) . | Adult AML . | M3 AML . | Normal/Int Cytogenetics* . | 8:21 or INV16 . | Poor-risk Cytogenetics** AML† . | 20 . | Elderly AML‡ . | Pediatric AML . | Survival . |
|---|---|---|---|---|---|---|---|---|---|
| * Normal and/or intermediate cytogenetics. This included patients with normal cytogenetics (studies 3, 8, 15, 16, and 19) and those lacking 15:17, 8:21, INV16, and poor-risk features. | |||||||||
| ** Poor-risk cytogenetics. This included patients with monosomy 5 or 7, 5q–, 3q–, or complex karyotype. | |||||||||
| † Secondary AML. This was defined as AML arising out of a myelodysplastic syndrome (MDS) and AML with trilineage myelodysplasia. Three of the studies listed (studies 1, 4 and 7) also included treatment-related AML in this group. | |||||||||
| ‡ Elderly AML patients were defined as being > 55 (study 6) or > 60 (study 4) years of age. | |||||||||
| § All 3 patients with high mutant-to-wild-type ratio in this study died. | |||||||||
| 1. Horiike et al (30) | 14.7% (5/34) | ND | |||||||
| 2. Kiyoi et al (74) | 20.3% (15/74) | Decreased | |||||||
| 3. Yamamoto et al (429) | 8.9% (81/429) | 28.0% (23/82) | 11.8% (4/34) | 18.2% (2/11) | Decreased | ||||
| 4. Rombouts et al (75) | 23.7% (14/59) | 24.2% (16/66) | 0.0% (0/6) | 18.2% (2/11) | 22.9% (8/35) | Decreased | |||
| 5. Abu-Duhier et al (106) | 10.0% (1/10) | 22.7% (10/44) | 5.8% (3/52) | Decreased | |||||
| 6. Stirewalt et al (140) | 33.6% (47/140) | No Effect | |||||||
| 7. Kottaridis et al (854) | 26.6% (227/854) | 36.8% (49/133) | 34.2% (96/281) | 8.3% (9/109) | 3.4% (5/147) | 27.4% (17/62) | Decreased | ||
| 8. Whitman et al (82) | 28.0% (23/82) | No Effect | |||||||
| 9. Iwai et al (94) | 5.3% (5/94) | Decreased | |||||||
| 10. Xu et al (87) | 13.8% (12/87) | Decreased | |||||||
| 11. Kondo et al (64) | 10.9% (7/64) | Decreased | |||||||
| 12. Meshinchi et al (91) | 16.5% (15/91) | Decreased | |||||||
| 13. Liang et al (80) | 11.3% (9/80) | No Effect§ | |||||||
| 14. Thiede et al (979) | 22.2% (217/979) | 33.3% (13/39) | 29.7% (134/451) | 4.5% (4/88) | 1.7% (5/298) | 8.8% (3/34) | Decreased | ||
| 15. Schnittger et al (1003) | 23.3.% (234/1003) | 35.8% 24/67) | 39.3% (149/379) | 5.4% (6/11) | 2.7% (3/110) | 15.6% (12/77) | No Effect | ||
| 16. Boissel et al (159) | 25.2% (40/159) | 35.4% (28/79) | 0.0% (0/23) | No Effect | |||||
| 17. Noguera et al (90) | 36.7% (33/90) | No Effect | |||||||
| 18. Frohling et al (523) | 22.8% (119/523) | 39.2% (20/51) | 31.7% (71/224) | 5.7% (4/70) | 2.2% (1/45) | 9.2% (7/76) | Decreased | ||
| 19. Kainz et al (100) | 38.1% (8/21) | 30.2% (16/53) | 7.7% (2/26) | Decreased | |||||
| 20. Moreno et al (208) | 17.3% (36/208) | 0.0% (0.14) | Decreased | ||||||
| 21. Jilani et al (85) | 21.2% (18/85) | Decreased | |||||||
| 22. Arrigoni et al (45) | 22.2% (10/45) | Decreased | |||||||
| 23. Zwaan et al (234) | 11.5% (27/234) | Decreased | |||||||
| TOTAL (4613 adult, 695 pediatric) | 22.9% (986/4299) | 33.6% (163/485) | 32.5% (566/1741) | 6.1% (32/527) | 2.6% (7/617) | 15.6% (46/294) | 31.4% (55/175) | 12.2% (85/695) | |